

**Referenser**

**CLINT – centrum för läkemedelsinformation i T-län**

**DOAK vid normal njurfunktion**

1. Jämförande värdering av NOAK vid förmaksflimmer [Internet]. 2024 [citerad 24 mars 2025]. Tillgänglig vid: <https://tinyurl.com/96ncu842aksflimmer.5.78ae827d1605526e94b8e791.html>
2. SAVAYSA label [Internet]. [citerad 24 mars 2025]. Tillgänglig vid [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2017/206316s012lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/206316s012lbl.pdf)
3. Lixiana (Filmdragerad tablett 60 mg) • FASS-text | FASS Vård [Internet]. [citerad 26 mars 2025]. Tillgänglig vid: <https://www.fass.se/LIF/product?userType=0&nplld=20150619000121>
4. Bohula EA, Giugliano RP, Ruff CT, Kuder JF, Murphy SA, Antman EM, m.fl. Impact of Renal Function on Outcomes With Edoxaban in the ENGAGE AF-TIMI 48 Trial. *Circulation*. 05 juli 2016;134(1):24–36.
5. Dabigatran Etexilate Accord (Kapsel, hård 75 mg) • FASS-text | FASS Vård [Internet]. [citerad 07 april 2025]. Tillgänglig vid: <https://www.fass.se/LIF/product?userType=0&nplld=20200630000010#caution>
6. Hijazi Z, Hohnloser SH, Oldgren J, Andersson U, Connolly SJ, Eikelboom JW, m.fl. Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis. *Circulation*. 04 mars 2014;129(9):961–70.
7. Hijazi Z, Hohnloser SH, Oldgren J, Andersson U, Connolly SJ, Eikelboom JW, m.fl. Efficacy and safety of dabigatran compared with warfarin in patients with atrial fibrillation in relation to renal function over time-A RE-LY trial analysis. *Am Heart J*. april 2018;198:169–77.